Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
Status:
Unknown status
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well panitumumab and combination chemotherapy works in
treating patients with metastatic colorectal cancer previously treated with combination
chemotherapy and bevacizumab. Monoclonal antibodies, such as panitumumab, can block tumor
growth in different ways. Some block the ability of tumor cells to grow and spread. Others
find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in
chemotherapy, such as leucovorin calcium, fluorouracil, and irinotecan hydrochloride, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Giving panitumumab and combination chemotherapy together may kill more
tumor cells